Last updated: February 23, 2026
What is NDC 16714-0979?
NDC 16714-0979 corresponds to Aflibercept (Eylea), a vascular endothelial growth factor (VEGF) inhibitor used primarily to treat wet age-related macular degeneration (AMD) and other retinal diseases. The drug is marketed by Regeneron Pharmaceuticals.
Current Market Status
Market Size & Revenue
As of 2022, the global ophthalmic drug market was valued at approximately $9.2 billion, with anti-VEGF agents representing a significant share. Eylea held around 60% of the anti-VEGF market in the U.S., generating $3.8 billion in revenue.
Competition Landscape
Major competitors include:
- Ranibizumab (Lucentis) by Genentech/Roche
- Bevacizumab (Avastin) by Genentech (off-label for ophthalmic use)
- Faricimab (Vabysmo) by Roche
Market Share Trends
Eylea has maintained a dominant position due to:
- Extended dosing intervals
- Proven efficacy
- Established clinician acceptance
Recent data indicates a slight decline in market share for Eylea, amid emerging therapies and off-label alternatives. However, it remains the leading agent in AMD treatment in North America.
Price Dynamics
List Prices
- Eylea (per injection): Approximately $2,100–$2,300 in the U.S.
- The average annual treatment cost ranges between $21,000 to $26,000, assuming 10–12 injections annually.
Reimbursement & Pricing Trends
Medicare and private insurers cover most costs, with negotiated discounts lowering patient out-of-pocket expenses. Patent protections through 2031 support stable pricing.
Price Projections (Next 5 Years)
| Year |
Estimated Price per Injection |
Estimated Annual Treatment Cost |
Key Factors |
| 2023 |
$2,150 |
$21,500 |
No significant price reduction; inflation-driven adjustments |
| 2024 |
$2,150 |
$21,500 |
Continued market dominance; patent exclusivity remains intact |
| 2025 |
$2,100 |
$21,000 |
Potential negotiation impacts; emerging biosimilars |
| 2026 |
$2,050 |
$20,500 |
Biosimilar launches anticipated; price competition increases |
| 2027 |
$2,000 |
$20,000 |
Entry of biosimilars could reduce list prices by up to 15–20% |
Impact of Biosimilar Competition
Dosing flexibility, improved efficacy, or reduced costs from biosimilars could cut Eylea's market share by 10–20% starting in 2026. Price discounts could reach 15–25%, depending on market acceptance.
Regulatory Environment and Patent Litigation
- Patent protections are valid through 2031, providing pricing stability.
- Patent litigation and patent cliffs in 2029–2030 may open opportunities for biosimilar entrants.
- Biosimilars approved by FDA could enter the market at 30–50% lower than Eylea's list price.
Market Risks & Opportunities
Risks
- Patent expiry leading to increased biosimilar competition
- Regulatory delays affecting new formulations or longer-acting versions
- Off-label use of cheaper alternatives
Opportunities
- Development of longer-acting formulations reducing injection frequency
- Expanding indications (e.g., diabetic retinopathy)
- Geographic expansion into emerging markets where pricing flexibility exists
Key Takeaways
- Eylea dominates the anti-VEGF retinal therapy market with around $3.8 billion annual revenue.
- Current list price per injection exceeds $2,100, with annual costs around $21,000.
- Price will likely remain stable until patent expiration or biosimilar entry, after which a 15–25% reduction is probable.
- Biosmilar competition beginning around 2025–2026 could significantly pressure prices and market share.
- Strategic focus on longer-acting formulations and broader indications offers growth opportunities.
FAQs
1. What factors influence Eylea's pricing over the next five years?
Patent protections, competition from biosimilars, regulatory changes, and negotiated discounts all affect pricing.
2. How will biosimilar entry impact Eylea’s market position?
Biosimilars could reduce Eylea's market share by up to 20%, with list prices decreasing by 15–25%.
3. Are there upcoming regulatory approvals that could affect the market?
Regulatory approval for longer-acting formulations or new indications could alter competitive dynamics post-2024.
4. How does Eylea’s pricing compare with key rivals?
Eylea maintains a higher price point than off-label Bevacizumab but offers longer dosing intervals than ranibizumab, justifying a premium.
5. What market segments offer growth potential?
Emerging markets and expanding indications for diabetic retinopathy and retinal vein occlusions present opportunities.
References
[1] Market research firms, 2022. Global Ophthalmic Drugs Market Report.
[2] Medicare reimbursement data, 2022.
[3] FDA biosimilar approvals, 2023.
[4] Regeneron Pharmaceuticals Inc. Annual Reports, 2022.
[5] Pharmaceutical pricing analysis, 2023.
